Track II: Issues of the Day Menopausal Depression and Premenstrual Dysphoric Disorder
Registration Options
Activity Date: 04/23/2018
AAPP 2018 registration is closed.
Session Time and Location
The live session is complete.
Target Audience
This course is designed for pharmacists, nurse practitioners or other healthcare professionals involved in the comprehensive medication management of psychiatric and/or neurological patients.
Session Summary
Emerging evidence suggests estrogen fluctuations across a woman’s lifespan impacts her susceptibility to experiencing depression. The link between menopause and depression has long been established. Pharmacists can play an important role in understanding the risks involved in this population as well as providing insights and education on pharmacologic treatment options to combat depression across the menopausal transition period.
Course Requirements
To receive ACPE credit for the live session at the Annual Meeting, you must:
Sign in (or create a FREE account).
Register for this course.
Attend and participate in the entire session and reflect upon its teachings.
Complete the evaluation at the end of the activity.
Provide the necessary details in your profile to ensure correct reporting by AAPP to CPE Monitor.
This course will be provided at the CPNP 2018 Annual Meeting, April 22-25, 2018. Upon successful completion, ACPE credit is reported immediately to CPE Monitor although transcripts can be retrieved by participants online at https://aapp.org/mycpnp/transcript/acpe.
AAPP has invested in supporting the most popular web browsers and leveraging software that our members use daily. Beyond PDF downloads, the rest of the system is built on HTML5, a technology that most up-to-date browsers will support. To access AAPP course materials online, you will need:
A modern web browser with JavaScript and cookies enabled: Chrome is strongly recommended,
or the latest version of Firefox or Safari.
A PDF reader: Chrome built-in, Firefox built-in, Acrobat
or FoxIt
An adequate device and Internet connection:
Processor: Dual-core 2Ghz or higher (Intel i3/i5/i7 or AMD equivalent);
Memory: 4 GB;
Storage: 5 GB available;
Internet speed: 4.0 Mbps (up/down)
AAPP web sites no longer fully support Microsoft Internet Explorer or Windows 8.1 and older. We cannot guarantee that the site will function perfectly on every device and configuration, but using the latest version of the software above will greatly improve your experience.
Marlene Freeman, MD
Associate Professor of Psychiatry, Harvard Medical School
Associate Director, Perinatal and Reproductive Psychiatry Program
Medical Director, CTNI
Newton, MA
Marlene P. Freeman, M.D. is an Associate Professor of Psychiatry, Harvard Medical School and the Abra Prentice Foundation Chair in Women’s Mental Health at Massachusetts General Hospital.
She is the Associate Director of the Center for Women’s Mental Health at Massachusetts General Hospital and the Medical Director of the MGH Clinical Trials Network and Institute (CTNI).
Dr. Freeman completed medical school at Northwestern University Medical School. She completed residency at the Harvard Longwood Psychiatry Residency Program and a research fellowship in the Biological Psychiatry Program at the University of Cincinnati College of Medicine. Her research and clinical expertise is in the areas of mood disorders and women’s mental health. She previously directed programs in women’s mental health at the University of Arizona College of Medicine and at UT-Southwestern in Dallas.
She is Editor-in-Chief for The Journal of Clinical Psychiatry (as of January 2018). She was a Distinguished Fellow of the American Psychiatric Association (APA), and chaired the APA Task Force on Complementary and Alternative Medicine, and was a member of the APA’s workgroup on Major Depressive Disorder treatment guidelines. She is on the Board of Directors of the American Society of Clinical Psychopharmacology (ASCP) and is a Member of the American College of Neuropsychopharmacology (ACNP). She also served as a Member of the Veterans Administration Reproductive Mental Health Steering Committee.
Faculty Disclosures
Grant/Research Support: Investigator Initiated Trials (Research): JayMac; Research: Sage; Independent Data Safety and Monitoring Committee: Janssen (Johnson& Johnson); Medical Editing: GOED newsletter.
Financial: Name of Organization(s): Dr. Freeman is an employee of Massachusetts General Hospital and works with the MGH National Pregnancy Registry [Current Registry Sponsors: Alkermes, Inc. (2016-Present); Otsuka America Pharmaceutical, Inc. (2008-Present); Forest/Actavis (2016-Present), Sunovion Pharmaceuticals, Inc. (2011-Present)]. As an employee of MGH, Dr. Freeman works with the MGH CTNI, which has had research funding from multiple pharmaceutical companies and NIMH.
Presentation will include discussion of off-label, experimental, and/or investigational use of drugs or devices: My presentation will include discussion of off-label, experimental, and /or investigational use of drugs or devices. Please indicate drugs and / or devices here: estradiol/estrogen, bupropion, gabapentin, paroxetine, venlafaxine, progesterone, fluoxetine, citalopram, escitalopram, desvenlafaxine, mirtazapine, duloxetine, vortioxetine, omega-3 fatty acids, black cohosh, multibotanicals, soy, hormone replacement therapy, sleep medications including zolpidem, sertraline, fluvoxamine, clomipramine, oral contraceptives, light therapy, calcium.
Affiliation: Investigator Initiated Trials (Research): JayMac; Research: Sage; Independent Data Safety and Monitoring Committee: Janssen (Johnson & Johnson); Medical Editing: GOED newsletter. Dr. Freeman is an employee of Massachusetts General Hospital, and works with the MGH National Pregnancy Registry [Current Registry Sponsors: Alkermes, Inc. (2016-Present); Otsuka America Pharmaceutical, Inc. (2008-Present); Forest/Actavis (2016- Present), Sunovion Pharmaceuticals, Inc. (2011-Present)]. As an employee of MGH, Dr. Freeman works with the MGH CTNI, which has had research funding from multiple pharmaceutical companies and NIMH.
All relevant relationships have been mitigated.
Learning Objectives
Explain the neurobiology of mood disorders of menopause and premenstrual dysphoric disorder (PMDD).
Describe the role of changing estrogen levels on an individual's susceptibility and experiencing depression during these phases.
Discuss the role of antidepressants and hormone replacement therapy and managing depressive symptoms in this population.
Evaluate an individual patient case to provide relevant patient education and treatment recommendations.
Continuing Education Credit and Disclosures
Activity Date: 04/23/2018 ACPE Contact Hours: 1 ACPE Number: 0284-0000-18-029-L01-P (Knowledge) Nursing Credit Reminder: Note that ACPE credit is accepted for certification renewal.
The College of Psychiatric and Neurologic Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This course provides 1.0 contact hour of knowledge-based continuing education credit from CPNP approved programming.
AAPP owns the copyright, is licensed or has received permissions for use of, or is otherwise permitted to use copyrighted materials within any CPE activity. Authors and speakers are required to obtain necessary copyright permissions for content in CPE activities. AAPP complies with copyright laws and regulations.
Elayne D. Ansara, PharmD, BCPP, BCPS
Clinical Pharmacy Specialist
Richard L. Roudebush VAMC
Indianapolis, IN
No Relevant Financial Relationships to Disclose
Jennifer Bean, PharmD, BCPP, BCPS
Clinical Pharmacy Specialist
VA-Tennessee Valley Healthcare System
Murfreesboro, TN
Employment: VA-Tennessee Valley Healthcare System, Clinical Pharmacy Specialist, University of Tennessee, College of Pharmacy Assistant Professor without Tenure
Educational Grants, Research Grants or Contracts: American Society of Health System, Federal Grant Co-Investigator
Jolene R. Bostwick, PharmD, BCPS, BCPP
Associate Chair & Clinical Associate Professor, Department of Clinical Pharmacy
University of Michigan College of Pharmacy
Ann Arbor, MI
No Relevant Financial Relationships to Disclose
Sheila R. Botts, PharmD, BCPP, FCCP
Chief of Clinical Pharmacy Research and Academic Affairs
Kaiser Permanente-Colorado
Aurora, CO
Educational Grants, Research Grants or Contracts: Kaiser Permanente Center for Safety and Effectiveness
Non-Financial Interests: Board of Pharmacetical Specialties Psychiatric Pharmacy Specialty Council
Bridget Bradley, PharmD, BCPP
Associate Professor
Pacific University School of Pharmacy
Hillsboro, OR
Educational Grants, Research Grants or Contracts: NACDS Community Pharmacy Residency Grant
Austin R. Campbell, PharmD, BCPP
Clinical Pharmacy Specialist - Psychiatry
University of Missouri Health Care
Columbia, MO
No Relevant Financial Relationships to Disclose
Andria F. Church, PharmD, BCPS
Assistant Professor
Larkin University College of Pharmacy
Miami, FL
No Relevant Financial Relationships to Disclose
Kelly N. Gable, PharmD, BCPP
Associate Professor
SIUE School of Pharmacy
Edwardsville, IL
External Consultant Activities, Advisory Panels, Speakers Bureaus, etc.: Places for People, Psychiatric Clinical Pharmacist, Family Care Health Centers, Psychiatric Clinical Pharmacist
Educational Grants, Research Grants or Contracts: SAMHSA GLS campus suicide prevention grant
Kristen N. Gardner, PharmD
Clinical Pharmacy Specialist - Behavioral Health
Kaiser Permanente Colorado
Denver, CO
Employment: Kaiser Permanente Colorado
Cindy A. Gutierrez, PharmD, BCPP, MS
Program Committee Chair
Associate Chief, Clinical Pharmacy Programs
South Texas Veterans Health Care System
San Antonio, TX
No Relevant Financial Relationships to Disclose
Robert J. Haight, PharmD, BCPP
Clinical Pharmacy Specialist-Psychiatry
University of MN Medical Center
Minneapolis, MN
External Consultant Activities, Advisory Panels, Speakers Bureaus, etc.: HealthPartners - Behavioral Health Advisory Group (Unpaid)
Michael Kotlyar, PharmD, MS
Associate Professor
University of Minnesota
Minneapolis, MN
No Relevant Financial Relationships to Disclose
Megan Maroney, PharmD, BCPP
Clinical Associate Professor
Ernest Mario School of Pharmacy at Rutgers, the State University of New Jersey
Long Branch, NJ
External Consultant Activities, Advisory Panels, Speakers Bureaus, etc.: Pharmacy Times, Jannsen Pharmacueticals - Advisory board, Otsuka Pharmaceuticals - Speakers Bureau
Leigh Anne Nelson, PharmD, BCPP
Associate Professor
University of Missouri-Kansas City
Kansas City, MO
External Consultant Activities, Advisory Panels, Speakers Bureaus, etc.: Alexza Pharmaceuticals
Educational Grants, Research Grants or Contracts: Otsuka, Eli Lilly
Rosana C. Oliveira, PharmD, BCPP, BCPS
Clinical Pharmacy Specialist - Psychiatry
South Texas Veterans Health Care System
San Antonio, TX
No Relevant Financial Relationships to Disclose
Gerald P. Overman, PharmD, BCPP
Program Administrative Chair
Clinical Pharmacy Specialist, NIMH
National Institutes of Health
Bethesda, MD
No Relevant Financial Relationships to Disclose
Emma C. Palmer, PharmD, BCPS, BCPP
Assistant Professor of Clinical and Administrative Sciences
Sullivan University College of Pharmacy
Louisville, KY
External Consultant Activities, Advisory Panels, Speakers Bureaus, etc.: Naloxone Access in Kentucky by Pharmacists- Certification contact hours provider
Educational Grants, Research Grants or Contracts: Sullivan University College of Pharmacy internal research grant
Non-Financial Interests: Kentucky Society of Health-Systems Pharmacists (KSHP) Chair of House of Delegates
Lindsey Peters, PharmD, BCPS
Assistant Professor of Pharmacy Practice
Ohio Northern University
Ada, OH
No Relevant Financial Relationships to Disclose
Melody Ryan, PharmD, BCPS, BCGP, FCCP
Professor
University of Kentucky
Lexington, KY
No Relevant Financial Relationships to Disclose
Kristyn Straw, PharmD, BCPP
Mental Health Pharmacist
Southern Arizona VA Health Care System
Tucson, AZ
No Relevant Financial Relationships to Disclose
Daina Wells, PharmD, BCPP, BCPS
National Program Manager, Academic Detailing
VACO PBM
San Francisco, CA
No Relevant Financial Relationships to Disclose
Gabriela D. Williams, PharmD, BCPS, BCPP
Clinical Pharmacy Specialist, Psychiatry
Eskenazi Health
Indianapolis, IN
No Relevant Financial Relationships to Disclose
Off-Label Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA (see faculty information and disclosures). The opinions expressed in the educational activity do not necessarily represent the views of AAPP and any educational partners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Presentation-Specific Disclosure: My presentation will include discussion of off-label, experimental, and /or investigational use of drugs or devices. Please indicate drugs and / or devices here: estradiol/estrogen, bupropion, gabapentin, paroxetine, venlafaxine, progesterone, fluoxetine, citalopram, escitalopram, desvenlafaxine, mirtazapine, duloxetine, vortioxetine, omega-3 fatty acids, black cohosh, multibotanicals, soy, hormone replacement therapy, sleep medications including zolpidem, sertraline, fluvoxamine, clomipramine, oral contraceptives, light therapy, calcium.
It is the policy of AAPP to ensure independence, balance, objectivity, scientific rigor, and integrity in continuing education activities. Those involved in the development of this continuing education activity have made all reasonable efforts to ensure that information contained herein is accurate in accordance with the latest available scientific knowledge at the time of accreditation of this continuing education activity. Information regarding drugs (e.g., their administration, dosages, contraindications, adverse reactions, interactions, special warnings, and precautions) and drug delivery systems is subject to change, however, and the reader is advised to check the manufacturer’s package insert for information concerning recommended dosage and potential problems or cautions prior to dispensing or administering the drug or using the drug delivery systems.
Fair balance is achieved through ongoing and thorough review of all materials produced by faculty, and all educational and advertising materials produced by supporting organizations, prior to educational offerings. Approval of credit for this continuing education activity does not imply endorsement by AAPP for any product or manufacturer identified.
AAPP websites use cookies to personalize and enhance your experience.
By continuing to use the site, you agree to this collection.
Learn more.
System Update:
We are undergoing major upgrades right now, and we appreciate your patience.
If you need help, please use the support chat or email info@aapp.org.
Learn more.